A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. [electronic resource]

By: Contributor(s): Producer: 20151026Description: 1667-75 p. digitalISSN:
  • 1468-2060
Subject(s): Online resources: In: Annals of the rheumatic diseases vol. 74
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.